Reshaping the HIV treatment and prevention landscape
World leading functional genomics platform
will enable our synthetic lethality pipeline
Zejula PRIMA study demonstrated the value
of synthetic lethality
-
Functional genomics studies suggested PARPS
should be effective beyond women with BRCAmut
- The PRIMA study proved this hypothesis.
by showing a benefit in all comers
The NEW ENGLAND
JOURNAL of MEDICINE
ESTABLISHED IN 1812
DECEMBER 19, 2019
VOL. 381 NO. 25
Niraparib in Patients with Newly Diagnosed Advanced
Ovarian Cancer
A. González-Martín, B. Pothuri, I. Vergote, R. DePont Christensen, W. Graybill, M.R. Mirza, C. McCormick,
D. Lorusso, P. Hoskins, G. Freyer, K. Baumann, K. Jardon, A. Redondo, R.G. Moore, C. Vulsteke, R.E. O'Cearbhaill,
B. Lund, F. Backes, P. Barretina-Ginesta, A.F. Haggerty, M.J. Rubio-Pérez, M.S. Shahin, G. Mangili,
W.H. Bradley, I. Bruchim, K. Sun, I.A. Malinowska, Y. Li, D. Gupta, and B.J. Monk,
for the PRIMA/ENGOT-OV26/GOG-3012 Investigators*
gsk
Expanding synthetic lethal pipeline with significant
opportunity for combinations
-
-
-
MAT2A has shown synthetic
lethality in tumours with MTAP
deletion - entered clinic
in 1H 2021
Pol Theta and Werner Helicase
in pre-clinical development
Bladder
MTAP Deletion Prevalence
Cancer Type
N
MTAP
deletions (%)
Glioblastoma
592
41
Mesothelioma
87
32
Esophageal
95
28
411
26
Pancreatic
184
22
Internal Functional Genomics
has identified > 12 targets
Melanoma
448
16
Lung Cancer (NSCLC)
1053
15
Head and Neck
523
14
Sarcoma
255
10
Esophagogastric
514
10
Diffuse Glioma
513
9
Breast
1084 3
Ovarian
585
3
Adrenocortical
92
3
Thymic
Hepatocellular
123
3
369
Renal non-clear cell
348
32
Source: The Cancer Genome Atlas in cBioPortal
94
56View entire presentation